Sanofi

In News

Sanofi strikes $1.5B global licensing deal for Sino Biopharm's first-in-class JAK/ROCK asset - Fierce Pharma

Fierce Pharma - Mar 04, 2026

Fierce Pharma Asia—Kyowa ends OX40 program; Sanofi licenses first-in-class drug; BioNTech advances Duality ADC - Fierce Pharma

Fierce Pharma - Mar 06, 2026

Updated: Sanofi licenses Sino Biopharm's 'breakout star' transplant drug for $135M upfront - Endpoints News

Endpoints News - Mar 05, 2026

Teva's $400M Blackstone deal to fund Sanofi-partnered IBD drug - Fierce Biotech

Fierce Biotech - Mar 04, 2026

Need Growing EPS And Dividends? Prescribe Sanofi (NASDAQ:SNY) - Seeking Alpha

Seeking Alpha - Mar 06, 2026

Podcast: Sanofi's head of clinical supply chain operations on evolving the clinical trial supply model - Clinical Trials Arena

Clinical Trials Arena - Mar 05, 2026

Blackstone to support Teva on Sanofi-partnered TL1A with $400M - Endpoints News

Endpoints News - Mar 04, 2026

Sanofi India Publishes Transcript of Investor Call on 2025 Financial Results - TipRanks

TipRanks - Mar 05, 2026

Blackstone puts $400M into Teva, Sanofi gut disease drug - BioPharma Dive

BioPharma Dive - Mar 04, 2026

Sanofi reports theft of insulin Lantus batch in India - ET Pharma

ET Pharma - Mar 03, 2026

Sanofi licenses rovadicitinib from Sino Biopharm in up to $1.5 billion deal - The Pharma Letter

The Pharma Letter - Mar 05, 2026

Sanofi to sell Medley unit to Brazil’s EMS (SNY:NASDAQ) - Seeking Alpha

Seeking Alpha - Mar 06, 2026

Stay Informed

Join our mailing list for the latest report releases and upcoming event notifications.

Headquartered in Boston, Mass., for over 50 years, BCC Research takes pride in being your trusted custom research and data analysts. Our mission is to provide businesses with reputable data and market research reports, so that they gain new perspectives into their field and better understand their target audience. We enable companies to access reliable information, accurate forecasts, and actionable insights, so that they may become leaders in their industry.

AI Sentiment